January 09, 2013
A Missouri federal judge on Tuesday refused to sanction Forest Laboratories Inc. over CEO Howard Solomon's deposition testimony in a multidistrict litigation over the suicide risks of the antidepressant drugs Lexapro and Celexa, ruling that Soloman did not behave inappropriately when answering questions.
October 15, 2012
Forest Laboratories Inc. urged a Missouri federal court on Friday to exclude expert testimony from two doctors in a multidistrict litigation over the suicide risks of the antidepressant drugs Lexapro and Celexa, arguing that the doctors did not show that they used proper methodology to reach their determinations.
May 28, 2009
A federal judge has shot down a bid to consolidate a newly filed proposed class action with multidistrict litigation over Lexapro and Celexa, saying the new product liability lawsuit asserts allegations relating to Forest Laboratories Inc.'s marketing of the drugs, while the MDL relates only to damages for personal injuries arising from suicidality.
July 25, 2008
A federal judge on Thursday denied Forest Laboratories Inc.'s motion to dismiss 22 actions in the Celexa and Lexapro multidistrict litigation because of the U.S. Supreme Court's decision to grant certiorari in Levine v. Wyeth, which also deals with the question of federal preemption in product liability suits.
November 20, 2007
Forest Laboratories Inc. on Monday asked a court to dismiss a product liability suit brought by the estate of a 74-year-old man who committed suicide after taking the antidepressant drug Lexapro.
October 22, 2007
A judge has denied a request by Forest Laboratories to dismiss eight suits in the multidistrict product liability litigation over antidepressants Celexa and Lexapro.
September 07, 2007
Forest Laboratories Inc. has asked the judge presiding over the multidistrict product liability litigation over blockbuster antidepressants Celexa and Lexapro to dismiss eight suits, arguing the plaintiffs should be punished for allegedly failing to comply with electronic discovery requirements in the wrongful death cases.
July 03, 2007
Forest Laboratories Inc. continues to fight allegations brought by about 35 families across the United States whose loved ones committed suicide while taking the antidepressants Lexapro and Celexa. The drug company maintains, however, that its medications improve and save, not destroy, lives.
June 21, 2007
Forest Laboratories has asked a judge to toss out one of the complaints in the Celexa and Lexapro multidistrict litigation, arguing that the wrongful death suit over the blockbuster antidepressant medications was improperly filed twice.
June 18, 2007
Forest Laboratories Inc. has urged a judge to deny the request of one of the plaintiffs in the multidistrict litigation involving blockbuster antidepressant drugs Celexa and Lexapro, arguing that time limitations prevent the addition of a Forest subsidiary to the complaint.